Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-valvular atrial fibrillation (an irregular heartbeat not caused by a heart valve problem), including types that come and go or are ongoing
- People between 18 and 80 years old
- People whose left atrium (one of the heart's chambers) measures less than 50mm across, as shown by an ultrasound of the heart
- People who a heart rhythm specialist has assessed as suitable for a procedure to isolate the pulmonary veins on both sides of the heart
- People who have agreed to undergo the ablation procedure
Who may not be able to join:
- People who have a blood clot found inside their heart, detected by a specific type of heart ultrasound performed via the throat (confirm with trial site)
- People who have an overactive thyroid gland (hyperthyroidism)
- People who have previously had a radiofrequency ablation procedure for atrial fibrillation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Quan Fang, M.D., Peking Union Medical College Hospital
Phone: +86-1069155068
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recurrence assessed by ECG, Holter reports and outpatient physicians; All-cause mortality assessed by telephone follow-up or medical records
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.